fashion -WSS

fashion

author：comprehensive 2025-09-09 19:28:35 - browse：22

JOSEPH PREZIOSO/AFP via Getty Images

Late-stage trial results for a pain medication developed by Vertex Pharmaceuticals reinforced experts’ sense that the drug was both safe and offered modest pain relief. But the findings also prompted fresh debate on Tuesday about how widely used the therapy would be should it win regulatory approval.

The company reported that its small molecule drug, VX-548, outperformed placebo in a pair of pain relief trials that recruited patients who had gotten an abdominoplasty (tummy tuck) or bunion surgery. The study also found that the drug was generally safe, with fewer patients on the medication reporting adverse events than those who had taken a placebo. But there was a catch: VX-548 didn’t outperform a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint. And in the bunionectomy study, the opioid comparator beat VX-548 on pain relief.

“While this study was not explicitly designed to test VX-548 vs. the opioid comparator, this may complicate the prescribing decision in the acute setting, where patients often take a short course of treatment and efficacy is a primary consideration,” Stifel market analyst Paul Matteis wrote in a note to investors, adding that results from three Phase 3 studies were positive overall.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Medical leaders decry Supreme Court decision on affirmative action

WSS

Why a market frenzy over new weight loss drugs defies logic

Wildfire smoke exposes gaps in outdoor worker protections

Is there really a nursing shortage in the U.S.?

Results on Novartis prostate cancer therapy could expand its use

Wildfire smoke exposes gaps in outdoor worker protections

Results on Novartis prostate cancer therapy could expand its use

focus

fashion

entertainment

Medicare proposal to cover medical devices draws a mixed reaction

Cancer drug shortages should be causing more outrage

Wildfire smoke exposes gaps in outdoor worker protections

Smaller biotechs seek to piggyback on weight loss drug boom

Duchenne breakthrough therapy leaves behind pioneering families

STAT Readout: Friday, Oct. 20 biotech updates

State Dept. review finds Biden bears some blame for Afghanistan failures

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Hepatitis C has a cure — but many Americans still lack access to it

Moonlake's readout produced a cash windfall. Risks remain

explore

What does generative AI mean for health care? We asked experts

Dobbs anniversary: the lost opportunity of abortion as health care

J&J lung cancer data amount to new salvo against AstraZeneca

FDA approval of Sarepta Duchenne genetic therapy gives me hope

CZI to create biohub to build anti

Trump demands the U.S. pay no more for drugs than other countries … again

Wikipedia

focus

explore

Wikipedia